| NCT00628433 |
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis |
PHASE1|PHASE2 |
COMPLETED |
Harbor Therapeutics |
Ulcerative Colitis |
DRUG: Placebo|DRUG: HE3286 |
Details |
| NCT04624230 |
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis |
PHASE3 |
RECRUITING |
Pfizer |
Ulcerative Colitis |
DRUG: tofacitinib |
Details |
| NCT06651281 |
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) |
PHASE3 |
RECRUITING |
Merck Sharp & Dohme LLC |
Crohn Disease|Colitis, Ulcerative |
DRUG: Tulisokibart|DRUG: Placebo to tulisokibart |
Details |
| NCT06681181 |
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants |
PHASE1 |
RECRUITING |
GlaxoSmithKline |
Colitis, Ulcerative |
DRUG: GSK4528287|DRUG: Placebo |
Details |
| NCT05180279 |
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis |
None |
COMPLETED |
Rush University Medical Center |
Ulcerative Colitis |
BEHAVIORAL: 7-day sleep lab |
Details |
| NCT03773952 |
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients |
PHASE2 |
COMPLETED |
Palobiofarma SL |
Ulcerative Colitis |
DRUG: PBF-677|DRUG: Placebo oral capsule |
Details |
| NCT06321887 |
EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD |
PHASE3 |
RECRUITING |
Liverpool University Hospitals NHS Foundation Trust |
Inflammatory Bowel Disease|Iron Deficiency Anemia |
DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… |
Details |
| NCT02762500 |
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
Lycera Corp. |
Colitis, Ulcerative |
DRUG: LYC-30937-EC|DRUG: Placebo |
Details |
| NCT04677179 |
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) |
PHASE2 |
TERMINATED |
Nektar Therapeutics |
Colitis, Ulcerative |
DRUG: LY3471851|DRUG: Placebo |
Details |
| NCT02958865 |
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis |
PHASE2 |
COMPLETED |
Pfizer |
Ulcerative Colitis |
DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… |
Details |
| NCT03943550 |
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) |
PHASE1 |
TERMINATED |
Hoffmann-La Roche |
Ulcerative Colitis |
DRUG: RO7049665|DRUG: Placebo |
Details |
| NCT04996797 |
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Ulcerative Colitis |
DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… |
Details |
| NCT01959282 |
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… |
Details |
| NCT05019742 |
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis |
PHASE2 |
RECRUITING |
Shanghai Pharma Biotherapeutics USA Inc. |
Ulcerative Colitis |
DRUG: SPH3127|DRUG: Placebo |
Details |
| NCT01759056 |
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis |
PHASE1 |
COMPLETED |
Avaxia Biologics, Incorporated |
Ulcerative Colitis |
DRUG: AVX 470|DRUG: Placebo |
Details |
| NCT03893565 |
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis |
PHASE2 |
TERMINATED |
GlaxoSmithKline |
Colitis, Ulcerative |
DRUG: GSK2831781 - Double Blind Phase|DRUG: Place… |
Details |
| NCT06049017 |
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
DRUG: JNJ-77242113|DRUG: Placebo |
Details |
| NCT01771224 |
Effect of FAn-7 in UC Activity |
EARLY_PHASE1 |
UNKNOWN |
National Institute of Medical Sciences and Nutrition, Salvador Zubiran |
Inflammatory Bowel Disease|Ulcerative Colitis |
DIETARY_SUPPLEMENT: Palmitoleic acid |
Details |
| NCT05784246 |
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis |
PHASE3 |
RECRUITING |
Eli Lilly and Company |
Ulcerative Colitis |
DRUG: Mirikizumab IV|DRUG: Mirikizumab SC |
Details |
| NCT03259308 |
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis |
PHASE3 |
TERMINATED |
Shire |
Ulcerative Colitis |
DRUG: Ontamalimab|DRUG: Placebo |
Details |
